Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353735 | 0.92 | SPR (0.42) | DYRK1AKDM4EALDH1A1HPGDFFAR4 | |
| SCHEMBL6340214 | 0.89 | DYRK1A (0.47) | DYRK1APARP1KDM4EALDH1A1HPGD | |
| SCHEMBL6344842 | 0.85 | SPR (0.43) | SPR | |
| SCHEMBL6342655 | 0.84 | SPR (0.43) | PARP1KDM4EALDH1A1HPGDSPR | |
| SCHEMBL6344363 | 0.84 | MAPT (0.43) | DYRK1AKDM4EALDH1A1HPGDFFAR4 | |
| SCHEMBL6339985 | 0.84 | L3MBTL1 (0.43) | ALDH1A1HPGDMAPT | |
| SCHEMBL6343219 | 0.82 | L3MBTL1 (0.40) | KDM4EALDH1A1HPGDFFAR4SPR | |
| SCHEMBL6350724 | 0.81 | KDM4E (0.44) | DYRK1AKDM4EALDH1A1HPGDSPR | |
| SCHEMBL6342685 | 0.81 | L3MBTL1 (0.41) | KDM4EALDH1A1HPGDFFAR4SPR | |
| SCHEMBL6353321 | 0.81 | PTGS2 (0.48) | PARP1KDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | DYRK1A 4242/4885PARP1 3752/4885KDM4E 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.